Qube Research & Technologies (QRT)
RETA

Qube Research & Technologies (QRT)’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-13,152
Closed -$400K – 3196
2022
Q2 		$400K Buy
+13,152
New +$392K ﹤0.01% 1496
2022
Q1 		– Sell
-17,810
Closed -$470K – 3177
2021
Q4 		$470K Buy
+17,810
New +$1.38M ﹤0.01% 1604
2020
Q3 		– Sell
-37,720
Closed -$5.88M – 2207
2020
Q2 		$5.88M Buy
+37,720
New +$5.73M 0.09% 302

Other funds holding RETA

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Qube Research & Technologies (QRT)'s RETA Position: Q3 2022 in Review

Qube Research & Technologies (QRT) sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2022, closing a stake of 13,152 shares — an estimated $400K sold.

Qube Research & Technologies (QRT) first reported a position in RETA in Q2 2020 and held it in 3 quarters. The position peaked at $5.88M in Q2 2020. 159 funds tracked by Wall St. Rank hold RETA as of Q3 2022.

  • Qube Research & Technologies (QRT) reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2022 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 13,152 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2022, an estimated $400K.
  • Qube Research & Technologies (QRT) first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2020 and held it in 3 quarters.
  • Qube Research & Technologies (QRT)'s Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $5.88M in Q2 2020.
  • 159 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2022.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q3 2022, filed 14 Nov 2022.